

All sections on this page are required unless otherwise specified. Important fields are highlighted. Incomplete information could result in a delay of testing.

result in a de	elay of testing.		
PATIENT IN	FORMATION		
First Name Last Name			
not realise	Lastituino		
Sex Assigned at Birth: OMale OFemale	Date of Birth (mm/dd/	′уу)	
Patient Karyotype (if known):			
Gender Identification (optional):			
mail			
ddress			
44.000			
ity	State	Zip Code	
		17.00	
rimary Phone	Is this patient decease Deceased Date:	d? O Yes ONo	
	Docodood Date.		
CAMPLEIN	CODMATION		
	FORMATION		
ate Sample Collected (mm/dd/yy)	Medical Record #		
O Blood O Bussel Street O Other (smart			
Blood Buccal Swab Other (specify	<u> </u>		
] Treatment-related RUSH (optional) eason: O Transplantation O Pregnancy (Date:		
atient has had a blood transfusion OYes (?-4 weeks of wait time is required for some to		instusion:	
atient has had an allogeneic bone marrow t			
broblasts are required for patients who had			
ee www.genedx.com/specimen-requirement			
atient has a personal history of a hematolog	gic malignancy or disea	ise	
		ONo	
yes, please call the lab to discuss with a gene	tic counselor the most ap	ppropriate sample type.	
PATIENT	CONSENT		
By signing this form, I acknowledge as the pa	itient or relative being te	sted that I have read	
or have had read to me the GeneDx Informed	d Consent document at	the end of this test	
equisition form, and understand the informo nave had the opportunity to ask questions al			
he risks, and the alternatives. By signing this			
esting as ordered. I understand that, for test			
members concurrently, test results from thes single comprehensive report that will be mad			
nealthcare providers.			
By checking this box, I confirm that I am			
permission for GeneDx to retain any rem	aining sample longer th	an 60 days after the	
permission for GeneDx to retain any rem completion of testing, and to be used as	aining sample longer th a de-identified sample	an 60 days after the for test development	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneD	aining sample longer th a de-identified sample uality assurance, and tra x to destroy my sample	an 60 days after the for test development ining purposes.	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneD cannot be used for test development stu	aining sample longer th a de-identified sample Jality assurance, and tra k to destroy my sample v Jalies.	an 60 days after the for test development ining purposes. within 60 days, and it	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDicannot be used for test development stu Check this box if you wish to opt out of both the complete in the com	aining sample longer th a de-identified sample vality assurance, and tra to destroy my sample valies. eing contacted for resec	an 60 days after the for test development ining purposes. within 60 days, and it arch studies	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDicannot be used for test development stu Check this box if you wish to opt out of both the complete in the com	aining sample longer th a de-identified sample vality assurance, and tra to destroy my sample valies. eing contacted for resec	an 60 days after the for test development ining purposes. within 60 days, and it	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDicannot be used for test development stu Check this box if you wish to opt out of be ignature of Patient/Legal Guardian (require	aining sample longer th a de-identified sample vality assurance, and tra to destroy my sample valies. eing contacted for resec	an 60 days after the for test development ining purposes. within 60 days, and it arch studies	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDicannot be used for test development stu Check this box if you wish to opt out of beignature of Patient/Legal Guardian (require	aining sample longer th a de-identified sample vality assurance, and tra to destroy my sample valies. eing contacted for resec	an 60 days after the for test development ining purposes. within 60 days, and it arch studies	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneD cannot be used for test development stu	aining sample longer th a de-identified sample vality assurance, and tra to destroy my sample valies. eing contacted for resec	an 60 days after the for test development ining purposes. within 60 days, and it arch studies	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDicannot be used for test development stu. Check this box if you wish to opt out of beignature of Patient/Legal Guardian (require ignature of Relative A/Legal Guardian	aining sample longer th a de-identified sample vality assurance, and tra to destroy my sample valies. eing contacted for resec	an 60 days after the for test development ining purposes. within 60 days, and it arch studies Date Date	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDicannot be used for test development stu Check this box if you wish to opt out of bignature of Patient/Legal Guardian (require ignature of Relative A/Legal Guardian GOR COMMERCIAL INSURANCE ONLY: By entering my preferred contact information by	aining sample longer th a de-identified sample uality assurance, and tra to destroy my sample idies. eing contacted for resected)	an 60 days after the for test development ining purposes. within 60 days, and it arch studies Date Date Date	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDx cannot be used for test development stu Check this box if you wish to opt out of brignature of Patient/Legal Guardian (require ignature of Relative A/Legal Guardian FOR COMMERCIAL INSURANCE ONLY: By entering my preferred contact information by the with an estimate of the patient's financial reference.	aining sample longer th a de-identified sample at to destroy my sample at the sample sample sample sample at the sample sa	an 60 days after the for test development ining purposes. within 60 days, and it arch studies Date Date Date	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDx cannot be used for test development stu Check this box if you wish to opt out of brignature of Patient/Legal Guardian (require ignature of Relative A/Legal Guardian FOR COMMERCIAL INSURANCE ONLY: By entering my preferred contact information by the with an estimate of the patient's financial reference.	aining sample longer th a de-identified sample uality assurance, and tra to destroy my sample idies. eing contacted for resected)	an 60 days after the for test development ining purposes. within 60 days, and it arch studies Date Date Date	
permission for GeneDx to retain any rem completion of testing, and to be used as and improvement, internal validation, qu Otherwise, New York law requires GeneDicannot be used for test development stu Check this box if you wish to opt out of beignature of Patient/Legal Guardian (require ignature of Relative A/Legal Guardian	aining sample longer th a de-identified sample atlity assurance, and tra t to destroy my sample idies. eing contacted for resec ed) elow, I give my permissio esponsibility for testing. De	an 60 days after the for test development ining purposes. within 60 days, and it arch studies Date Date Date n to GeneDx to contact ata rates may apply.	

ACCOUNT INFORMATION				
GeneDx Account Number	Account Name			
Phone	Fax			
Address	<u> </u>			
City	State	Zip Code		
Ordering Provider Name		Role/Title		
NPI	Phone Number			
Send Report Via: ☐ Fax ☐ Email ☐ Portal Fax #/Email:	l			
Additional Ordering Provider Name (optional))	Role/Title		
NPI				
Send Report Via: Fax Email Portal				
Fax #/Email:				
SEND ADDITIONAL REPORT COPIES TO (optiona	1)			
Provider Name	GeneDx Acct#			
Fax #/Email:				

STATEMENT OF MEDICAL NECESSITY

By submission of this test requisition and accompanying sample(s), I: (i) authorize and direct GeneDx to perform the testing indicated; (ii) certify that the person listed as the ordering provider is authorized by law to order the test(s) requested; (iii) certify that any custom panel and/or ordered test(s) requested on this test requisition form are reasonable and medically necessary for the diagnosis and/or treatment of a disease, illness, impairment, symptom, syndrome or disorder; (iv) the test results will determine my patient's medical management and treatment decisions of this patient's condition on this date of service; (v) have obtained this patient's and relatives', when applicable, written informed consent to undergo any genetic testing requested; and (vi) that the full and appropriate diagnosis code(s) are indicated to the highest level of specificity.

Signature of Ordering Provider

ICD-10-CM CODES			
ICD-10-CM Codes			
Clinical Diagnosis	Age of Onset		

	PAYMENT O	PTIONS (Sele	ect One)		
O INSURANCE BILL Select all that apply Commercial	Patient Status OHospital outpation Not a hospital po		itient; Date of Dischar	ge:	
☐ Medicaid ☐ Medicare	Name of Insurance	e Carrier	Insurance ID#:		
☐ Tricare ☐ CHAMPVA	Relationship to Insured OSelf Ospouse Ochild Oother:				
FOR ALL INSURANCE PROVIDE FRONT AND BACK COPY OF CARD(S)	Policy Holder's Name		Policy Holder's Date of Birth		
	Referral/Prior Authorization # (please attach)		Hold test for cost estimate and contact patient if estimate is >\$250 (commercial insurance only)		
	Secondary Insurance Type:				
	Insurance Carrier	Insurance ID #	Subscriber Name	Date of Birth	
	Relationship to Insured OSelf OSpouse Ochild Oother:				
O PATIENT BILL	If Patient Bill is selected, I am electing to be treated as a self-pay patient for this testing. I agree that neither GeneDx nor I will submit a claim to my insurance for this testing, if I have insurance. GeneDx will se				
	Authorized Patient/Guardian Signature				
O INSTITUTIONAL BILL	GeneDx Account #	<i>‡</i>	Discos Objete dobres de la company		
	Hospital/Lab Name		Place Sticker/Stamp Here		



First Name Last Name Date of Birth

CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED)			
Is this person affected? O Yes O No Clinical diagnosis:			
Reason for testing: Diagnosis Presymptomatic diagnosis Carrier/Familial Variant Testing			
Please check all that apply. This is not a substitute	for submitting clinical records.		
Pre/Perinatal History	Neurological Findings	Eye Defects/Vision	
□ Cystic hygroma	☐ Abnormality of nervous system	□Aniridia	
□ Decreased body weight	☐ Ataxia	□ Anophthalmia	
□ Diaphragmatic hernia	☐ Cerebral palsy	Astigmatism	
☐ Growth delay	Cortical visual impairment	☐ Cataracts	
□ Increased body weight □ Intrauterine growth retardation	□ Dysarthria □ Dysphasia	□ Coloboma □ Corneal opacity	
□ Neural tube defect	□ Dystonia	□ Ectopia lentis	
☐ Nonimmune hydrops fetalis	☐ Encephalopathy		
□ Oligohydramnios	Epileptic encephalopathy	□ Exotropia	
Polyhydramnios	☐ Generalized seizures	□ External ophthalmoplegia	
Prematurity GA:	Headaches	Microphthalmia	
□ Prolonged neonatal jaundice	☐ Hyperreflexia	Myopia	
	□ Infantile spasms □ Limb hypertonia	□ Nystagmus □ Optic atrophy	
Structural Brain Abnormalies	Myoclonus	Optic atrophy	
□ Abnormality of basal ganglia	□ Parkinsonism	□ Ptosis	
☐ Abnormality of brainstem	Peripheral neuropathy	Retinitis pigmentosa	
☐ Abnormality of periventricular white matter	Seizures	Strabismus	
☐ Abnormality of the corpus callosum	☐ Sensory neuropathy	Visual impairment	
□ Aplasia/hypoplasia of cerebellar vermis □ Aplasia/hypoplasia of cerebellum	☐ Spasticity	Hogring Impairment	
☐ Apidsid/Hypopidsid of cerebellarif	□ Stroke-like episode □ Syncope	Hearing Impairment Aminoglycoside-induced hearing loss	
☐ Cerebellar atrophy	☐ Tremors	Conductive hearing impairment/bilateral	
□ Cerebellar hypoplasia (Pontocerebellar	□ Vertigo	Hearing impairment	
hypoplasia)	_ 0	☐ Sensorineural hearing impairment/bilateral	
CNS hypomyelination	Craniofacial/Dysmorphism		
☐ Cortical dysplasia	☐ Abnormal facial shape (Dysmorphic	Cardiac Findings	
☐ Holoprosencephaly ☐ Hydrocephalus	features)	☐ Abnormal echocardiogram	
☐ Leukodystrophy	☐ Abnormality of philtrum	☐ Abnormal heart morphology	
Lissencephaly	Anteverted nares	□ Abnormal heart valve morphology	
□ Pachygyria	□ Brachycephaly □ Broad forehead	Arrhythmia	
Polymicrogyria	☐ Bulbous nose	☐ Atrial septal defect	
Pontocerebellar atrophy	☐ Cleft lip	□ Cardiomegaly □ Cardiomyopathy	
□ Ventriculomegaly	□ Cleft palate	☐ Dilated cardiomyopathy	
	☐ Coarse facial features	☐ Hypertension	
Developmental/Behavioral Findings	☐ Craniosynostosis	☐ Hypertrophic cardiomyopathy	
☐ Abnormal aggressive, impulsive or violent	□ Deeply set eye □ Dental crowding	Palpitations	
behavior	Depressed nasal bridge	☐ Tachycardia	
Abnormal social behavior	□ Epicanthus	□ Ventricular septal defect	
☐ Absent speech ☐ Attention deficit hyperactivity disorder	☐ Facial asymmetry		
☐ Attention deficiently perdetivity disorder ☐ Autistic behavior	Frontal bossing	Respiratory Findings	
☐ Clumsiness	☐ High palate	Apnea	
□ Cognitive impairment	☐ Hypertelorism ☐ Hypotelorism		
□ Delayed fine motor development	Long face	☐ Asthma ☐ Hyperventilation	
☐ Delayed gross motor development	□ Low set ears	☐ Hypoventilation	
☐ Delayed speech & language development☐ Developmental regression	□ Macrocephaly	Recurrent upper respiratory infections	
☐ Dysarthria	Microcephaly	☐ Respiratory distress	
☐ Frequent falls	☐ Micrognathia	□ Respiratory insufficiency	
Gait disturbance	☐ Midface retrusion ☐ Prominent nasal bridge		
☐ Global developmental delay	☐ Retrognathia	Gastrointestinal Findings	
☐ Incoordination	Synophrys	☐ Constipation	
Intellectual disability Memory impairment	☐ Wide nasal bridge	□ Diarrhea	
Memory impairment Sleep disturbance	☐ Wide spaced teeth	Exocrine pancreatic insufficiency	
Specific learning disability		☐ Failure to thrive	
Speech articulation difficulties		☐ Feeding difficulties ☐ Gastroesophageal reflux	
Stereotypy		Gastrointestinal dysmotility	
		, ,	



First Name Last Name Date of Birth

CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED) **Gastrointestinal Findings** (continued) **Genitourinary Findings Endocrine Findings** □ Gastroparesis ☐ Ambiguous genitalia ☐ Diabetes Insipidus ☐ Hepatomegaly ☐ Cryptorchidism ☐ Diabetes Mellitus ☐ Inflammatory bowel disease ☐ Glomerulosclerosis ☐ Hyperthyroidism Laryngomalacia ☐ Hydronephrosis ☐ Hypothyroidism □Nausea ☐ Hypospadias □ Pancreatitis ☐ Inguinal hernia **Vascular System** ☐ Pyloric stenosis □ Polycystic kidney disease ☐ Stroke □ Splenomegaly □ Renal agenesis ☐ Thromboembolism ☐ Tracheoesohageal fistula ☐ Renal insufficiency □ Vomiting ☐ Renal tubular acidosis ☐ Renal tubular dysfunction ☐ Urinary incontinence **Musculoskeletal Findings** ☐ Abnormal connective tissue ☐ Abnormal form of the vertebral bodies Metabolic Issues/Mito (Attached relevant lab reports/values) ☐ Abnormality of joint mobility ☐ Abnl Plasma AA result: _ ☐ Arthrogryposis ☐ Abnl Urine OA result: ☐ Bruising susceptibility ☐ Abnormal activity of mitochondrial respiratory chain ☐ Craniosynostosis ☐ Abnormal mitochondria in muscle tissue ☐ Decreased muscle mass ☐ Abnormal Newborn Screen result: ☐ Dolichocephaly ☐ Abnormality of mitochondrial metabolism ☐ Dysostosis multiplex ☐ Cytochrome C oxidase-negative muscle fibers ☐ Elevated serum creatine phosphokinase ☐ Decreased activity of mitochondrial ATP synthase complex ☐ Exercise intolerance ☐ Decreased activity of mitochondrial respiratory complexes □ Fasciculations ☐ Decreased activity of the pyruvate dehydrogenase complex □ Fatigue □ Depletion of mitochondrial DNA in liver ☐ Flexion contracture Depletion of mitochondrial DNA in muscle tissue ☐ Hemihypertrophy ☐ Elevated CPK: ☐ Hypertonia ☐ Elevated hepatic transaminases ☐ Hyperammonemia ☐ Hypotonia ☐ Joint hypermobility ☐ Hypoammonemia ☐ Muscle cramps ☐ Hypoglycemia ☐ Muscle weakness ☐ Increased serum pyruvate ☐ Myalgia □ Lactic acidosis ☐ Myopathy ☐ Multiple mitochondrial DNA deletions ☐ Pectus excavatum ☐ Subsarcolemmal accumulations of abnormally shaped mitochondria □ Pes planus ☐ Vitamin D deficiency ☐ Ptosis □ Rhabdomyolysis ☐ Scoliosis ☐ Short stature ☐ Skeletal dysplasia Skin/Hair Findings □ Alopecia ☐ Angiokeratoma ☐ Brittle hair □ Café-au-lait macules ☐ Coarse hair ☐ Dry skin □ Eczema □Hemangiomas ☐ Hyperextensible skin ☐ Hyperpigmentation of the skin ☐ Hypertrichosis ☐ Hypopigmentation of the skin ☐ Ichthyosis ☐ Skin rash ☐ Sparse hair □ Velvety skin (Soft skin) ☐ Xanthomatosis



First Name	Last Name Date of Birth						
						<u> </u>	
FAMILY HISTORY							
□ No Known Family History	□ Pe	edigree Atto	ached	□Adopted			
Relationship	Maternal	Paternal	Relevant History			Age at Dx	
1	0	0					
2	0	0					
3	0	0					
			PREVIOUS GEN	NETIC TESTING			
Personal or family history of	f genetic test	ing ON	lo O Yes (If yes, pl	ease complete all field	ds below)		
Relation to patient (self, sibling,	etc.), Genetic T	est(s) and Re	esult (e.g. positive, nego	ative, etc.). If relative was	tested at GeneD	x, please also provide thei	r accession #:
If patient or relative(s) were foundicate any Variants of Interes			IS result on prior testing	, please provide details b	elow.		
Relation (self, sibling, etc.)	Gene	Transcrip	ot # c./p. (SN	V) or exon # (CNV)	Build, d	coordinates (CNV)	Variant of
1							Interest‡?
2							
3							
Required for sequence variants: gene, c./p., transcript #							
Required for CNVs: gene, transcript #, exon # OR build, coordinates							
Abnormal karyotype, FISH, or ot	ner results: ——						
‡ For certain tests, GeneDx may be able to specifically comment upon the presence or absence of previously identified variant(s) of interest in the report. Complete variant information must be provided in the table above at the time the test order is placed. If you do not complete the table above and check off that a previously identified variant is a variant of interest, it will							
not be possible to comment upon the presence or absence of the variant in the report retrospectively. This service is not applicable to targeted variant testing.							
TARGETED VARIANT TESTING							
Individual to be tested: O Affected/Symptomatic OUnaffected/Asymptomatic UKnown Familial Variant(s) in a Nuclear Gene UConfirmation of Variant Identified in Research Lab UTargeted Mosaic Variant Testing							
☐ Known Familial Copy Number			Confirmation of Variant(Known mtDNA Variant(s		(Insuranc	Mosaic Variant Testing e Billing NOT Accepted; Po	
institutional Bill MUST be selected on page 1) Proband Name Relationship to Proband Proband GeneDx Accession #				n page 1)			
Nan OanaDu Taab			-ll (
□Positi	ve control inclu	ided/will be s	sent - Positive control i	orevious test was perform s recommended if previon ncluded on a negative re	ous test was perf		
VARIANT INFORMATION (-	se fill out the below information if family member report is not included) Number of Variants:					
Gene		g DNA (c./m.)		Amino Acid (p.)		Transcript (NM#)	
Gene	Codin	g DNA (c./m.)		Amino Acid (p.)		Transcript (NM#)	
COPY NUMBER VARIANT						Number of Variants:	
Gene(s)	Exon #			Coordinates		Genome Build	
Gene(s)	Exon #	ŧ		Coordinates		Genome Build	



First Name Last Name Date of Birth **TEST MENU TEST CODE TEST NAME TEST CODE TEST NAME** MITOCHONDRIAL DISORDERS GENETIC TESTING ☐ 615 Combined Mito Genome Plus Mito Focused Nuclear Gene Panel □ 554 Full sequence analysis and deletion testing of the mitochondrial genome ☐ TH12 Leber Hereditary Optic Neuropathy (LHON) Panel METABOLIC DISORDERS GENETIC TESTING □ J976 Creatine Deficiency Syndromes Panel □ TG90 Primary Hyperoxaluria Panel □ T012 Metabolic Myopathy Panel INBORN ERRORS OF METABOLISM SINGLE GENE TESTS (The following tests include sequencing and deletion/duplication testing unless otherwise noted) □ 564 Canavan disease (ASPA) □ T387 Mucopolysaccharidosis type II (Hunter syndrome) (IDS sequencing, del/dup recombination analysis) 713 Fumarate hydratase deficiency (FH) □ 273 Phenylalanine hydroxylase (PAH) ☐ 349E Galactosemia / Galactosyltransferase deficiency (GALT) □ 365 Primary/systemic carnitine deficiency (SLC22A5) ☐ TG94 Gaucher disease (GBA sequencing only) 270 Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency (ACADVI) ☐ TH08 Glycogen storage disease type II (Pompe disease) (GAA) ☐ TG92 Wilson disease (ATP7B) Medium chain acyl-CoA dehydrogenase (MCAD) deficiency J975 2682 X-linked adrenoleukodystrophy (ABCDI) (ACADM) CUSTOM DEL/DUP TESTING □ 906 Deletion/Duplication Analysis of ONE Nuclear Gene □ 703 Deletion/Duplication Analysis of 2-20 Nuclear Genes Write-in Desired Gene(s) to be Tested:

	DID YOU REMEMBER TO?
☐ Label specimen tube appropriately with TWO identifiers☐ Get a signature for medical necessity and patient consent	

Test Name:

GeneDx tests are frequently updated and improved based upon the most recent scientific evidence. The test codes, genes, and gene quantities listed on this test requisition are subject to change by GeneDx at any time. The most current test menu, list of genes, and technical limitations included for a specific test panel may be found on our website, genedx.com. Please note that GeneDx reserves the right to modify and upgrade any ordered panel to the version currently listed on our website.

WRITE-IN TEST SELECTION

☐ Test Code:



First Name Last Name Date of Birth

For the purposes of this consent, "I", "my", and "your" will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or pass on a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

- 1. <u>Positive</u>: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.
- 2. Negative: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.
- 3. <u>Variant of Uncertain Significance (VUS)</u>: A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.
- 4. <u>Unexpected Results</u>: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. We may disclose this information to the ordering healthcare provider if it likely affects medical care.

Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information GeneDx used to interpret my results. Healthcare providers can contact GeneDx at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of the test results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents.

Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that GeneDx will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information about a relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

- 1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.
- 2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.
- 3. Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.
- 4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.
- 5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.

To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information. More information can be found at: www.genome.gov/10002077

INTERNATIONAL SAMPLES

If I reside outside the United States, I attest that by providing a sample for testing, I am not knowingly violating any export ban or other legal restriction in the country of my residence.

SAMPLE RETENTION

After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. GeneDx will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made.

I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and GeneDx will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. GeneDx will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION

De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this deidentified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. GeneDx shares this type of information with healthcare providers, scientists, and healthcare databases. GeneDx will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. GeneDx believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.



First Name Last Name Date of Birth

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

- Applicable Only for Full Exome Sequencing and Genome Sequencing Tests.
- Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features.

The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT?

All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing or a minimum of 15X coverage was achieved by genome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES?

The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS

Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified nor reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE

For insurance billing, I understand and authorize GeneDx to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to GeneDx.

I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by GeneDx as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by GeneDx on my behalf, I agree to endorse the insurance check and forward it to GeneDx within 30 days of receipt as payment towards GeneDx's claim for services rendered.

If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by GeneDx. I further understand and agree that, if I fail to make payment for genetic testing, in accordance with the payment policies of GeneDx, my account may be turned over to an external collection agency for non-payment. I agree to pay any associated collection costs, including attorney fees. By my signature on the GeneDx Test Requisition Form or at the bottom of this form, I accept full and complete financial responsibility for all genetic testing ordered by my healthcare provider.

MEDICARE

A completed Advance Beneficiary Notice (ABN) is required for Medicare patients, when applicable. Please visit our website, www.genedx.com/billing for more information.